These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7858972)

  • 21. The immune response against hapten-autologous protein conjugates in the mouse.
    Rubin B; Wigzell H
    J Exp Med; 1973 Apr; 137(4):911-31. PubMed ID: 4540327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescent probes for antibody active sites. I. Production of antibodies specific to the N-methyl-2-anilinonaphthalene-6-sulfonyl group in rabbits and some fluorescent properties of the hapten bound to the antibodies.
    Onodera M; Shiokawa H; Takagi T
    J Biochem; 1976 Jan; 79(1):195-202. PubMed ID: 780348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polyclonal catalytic antibodies.
    Gallacher G
    Biochem Soc Trans; 1993 Nov; 21(4):1087-90. PubMed ID: 8131904
    [No Abstract]   [Full Text] [Related]  

  • 24. First example of an antibody-catalyzed aza Diels-Alder reaction.
    Shi ZD; Yang BH; Wu YL; Pan YJ; Ji YY; Yeh M
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2321-4. PubMed ID: 12161125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural convergence in the active sites of a family of catalytic antibodies.
    Charbonnier JB; Golinelli-Pimpaneau B; Gigant B; Tawfik DS; Chap R; Schindler DG; Kim SH; Green BS; Eshhar Z; Knossow M
    Science; 1997 Feb; 275(5303):1140-2. PubMed ID: 9027317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-hapten IgG antibodies bound to cell surface hapten: anti-IgG antibody prevents dissociation as measured with fluid phase hapten.
    Borsos T; Circolo A; Young-Cooper GO; Mage R
    J Immunol; 1986 Jan; 136(1):224-9. PubMed ID: 3079609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting of antihapten antibodies to activated T cells via an IL-2-hapten conjugate prolongs cardiac graft survival.
    Lussow AR; Fanget L; Gao L; Block M; Buelow R; Pouletty P
    Transplantation; 1996 Dec; 62(12):1703-8. PubMed ID: 8990347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shifts from IgG-2 class to IgG-1 class in CBA and C3H anti-BALB/c antibody.
    Harris TN; Harris S
    Transplantation; 1975 Apr; 19(4):318-25. PubMed ID: 1098236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of three selenium-containing catalytic antibodies with high catalytic efficiency using a novel hapten design method.
    Su D; Ren X; You D; Li D; Mu Y; Yan G; Zhang Y; Luo Y; Xue Y; Shen J; Liu Z; Luo G
    Arch Biochem Biophys; 2001 Nov; 395(2):177-84. PubMed ID: 11697854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The sheep immune response. Variation of anti-hapten and anti-carrier antibodies in the 1 and 2 immunoglobulin fractions.
    Margni RA; Castrelos OD; Paz CB
    Immunology; 1973 May; 24(5):781-9. PubMed ID: 4123676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of various adjuvants on the synthesis of specific antibodies of chicken, sheep and rabbit following immunization with an hapten.
    Erhard M; Kellner J; Kühlmann R; Lösch U
    Zentralbl Veterinarmed A; 1991 Feb; 38(1):21-7. PubMed ID: 1905862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new strategy for the generation of catalytic antibodies.
    Shokat KM; Leumann CJ; Sugasawara R; Schultz PG
    Nature; 1989 Mar; 338(6212):269-71. PubMed ID: 2922053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppression of anti-hapten IgE and IgG antibody responses by isologous anti-idiotypic antibodies against purified anti-carrier (ovalbumin) antibodies in BALB/c mice.
    Blaser K; Nakagawa T; de Weck AL
    J Immunol; 1981 Mar; 126(3):1180-4. PubMed ID: 7462630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production of IgM and IgG antibodies specific for AMP in rabbits by immunization with AMP-E. coli conjugate.
    Furuichi K; Sasaki T; Koyama J
    J Biochem; 1973 Sep; 74(3):451-7. PubMed ID: 4585707
    [No Abstract]   [Full Text] [Related]  

  • 35. Carbon nanotube-protein carriers enhance size-dependent self-adjuvant antibody response to haptens.
    Parra J; Abad-Somovilla A; Mercader JV; Taton TA; Abad-Fuentes A
    J Control Release; 2013 Sep; 170(2):242-51. PubMed ID: 23735572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New strategies for the design of catalytic antibodies.
    Janda KD
    Biotechnol Prog; 1990; 6(3):178-81. PubMed ID: 1366610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies as drug carriers. II. For proteins.
    Rehlaender BN; Cho MJ
    Pharm Res; 2001 Jun; 18(6):753-60. PubMed ID: 11474778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell co-operation and hapten--carrier complexes.
    Snippe H; Kamp E
    Immunology; 1975 Oct; 29(4):675-85. PubMed ID: 52618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The suppressive effect of carrier priming on the response to a hapten-carrier conjugate.
    Elson CJ; Taylor RB
    Eur J Immunol; 1974 Oct; 4(10):682-7. PubMed ID: 4609768
    [No Abstract]   [Full Text] [Related]  

  • 40. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
    Wenthur CJ; Cai X; Ellis BA; Janda KD
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.